# A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects

> **NCT04703374** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 48 (estimated)

## Conditions studied

- GERD

## Interventions

- **DRUG:** CKD-382(formulation I)
- **DRUG:** CKD-382(formulation II)
- **DRUG:** D026

## Key facts

- **NCT ID:** NCT04703374
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-25
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04703374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04703374, "A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04703374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*